SEARCH

SEARCH BY CITATION

References

  • 1
    Manns MP, McHutchinson JG, Gordon SC, et al. Peginterferon-alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomized trial. Lancet 2001; 358: 95865.
  • 2
    Fried MW, Shiffman ML, Reddy KR, et al. Combination of peginterferon alfa-2a (40 kd) plus ribavirin in patients with chronic hepatitis C virus infection. N Eng J Med 2002; 347: 97582.
  • 3
    Hadziyannis SJ, Sette H Jr, Morgan TR, et al. Peginterferon-alfa 2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose. Ann Intern Med 2004; 140: 34655.
  • 4
    McHutchison JG, Lawitz EJ, Shiffman ML, et al. Peginterferon alfa-2b or alfa-2a with ribavirin for treatment of hepatitis C infection. N Eng J Med 2009; 361: 58093.
  • 5
    Poordad F, McCone J Jr, Bacon BR, et al. Boceprevir for untreated chronic HCV genotype 1 infection. N Engl J Med 2011; 364: 1195206.
  • 6
    Jacobson IM, McHutchison JG, Dusheiko G, et al. Telaprevir for previously untreated chronic hepatitis C virus infection. N Engl J Med 2011; 364: 240516.
  • 7
    Sherman KE, Flamm SL, Afdhal NH, et al. Telaprevir in combination with peginterferon and ribavirin for 24 or 48 weeks in treatment naïve genotype 1 HCV patients who achieved an extended rapid virologic response: final results of phase 3 Illuminate study. Hepatology 2010; 52(Suppl.): 401A.
  • 8
    Bacon BR, Gordon SC, Lawitz E, et al. Boceprevir for previously treated chronic HCV genotype 1 infection. N Engl J Med 2011; 364: 120717.
  • 9
    Zeuzem S, Andreone P, Pol S, et al. Telaprevir for retreatment of HCV infection. N Engl J Med 2011; 364: 241728.
  • 10
    Shiffman ML. HCV response guided therapy: should treatment length be shortened or extended? Curr Hepat Rep 2011; 10: 410.
  • 11
    Jensen DM, Morgan TR, Marcellin P, et al. Early identification of HCV genotype 1 patients responding to 24 weeks peginterferon alpha-2a (40 kd)/ribavirin therapy. Hepatology 2006; 43: 95460.
  • 12
    Ferenci P, Laferl H, Scherzer TM, et al. Peginterferon alfa-2a and ribavirin for 24 weeks in hepatitis C type 1 and 4 patients with rapid virological response. Gastroenterology 2008; 135: 4518.
  • 13
    Lee SS, Sherman M, Ramji A, et al. 36 versus 48 weeks of treatment with peginterferon alfa-2a plus ribavirin for genotype 1/4 patients with undetectable HCV RNA at week 8: final results of a randomized multicenter study. Hepatology 2010; 52(Suppl.): 359A.
  • 14
    Fried MW, Hadziyannis SJ, Shiffman ML, Messinger D, Zeuzem S. Rapid virological response is the most important predictor of sustained virological response across genotypes in patients with chronic hepatitis C virus infection. J Hepatol 2011; 55: 6975.
  • 15
    Berg T. Tailored treatment for hepatitis C. Clin Liver Dis 2008; 12: 50728.
  • 16
    Shiffman ML. Treatment of HCV in 2011. What can we expect? Curr Gastroenterol Rep 2010; 12: 707.
  • 17
    Asselah T, Bieche I, Narguet S, et al. Liver gene expression signature to predict response to pegylated interferon plus ribavirin combination therapy in patients with chronic hepatitis C. Gut 2008; 57: 51624.
  • 18
    Susser S, Welsch C, Wang Y, et al. Characterization of resistance to the protease inhibitor boceprevir in hepatitis C virus-infected patients. Hepatology 2009; 50: 170918.
  • 19
    Susser S, Vermehren J, Forestier N, et al. Analysis of long-term persistence of resistance mutations within the hepatitis C virus NS3 protease after treatment with telaprevir or boceprevir. J Clin Virol 2011; 52: 3217.
  • 20
    Ge D, Fellay J, Thompson AJ, et al. Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance. Nature 2009; 461: 399401.
  • 21
    Thompson AJ, Muir AJ, Sulkowski MS, et al. IL28B Polymorphism improves viral kinetics and is the strongest pre-treatment predictor of SVR in HCV-1 patients. Gastroenterology 2010; 139: 1209.
  • 22
    Afdhal NH, McHutchison JG, Zeuzem S, et al. Hepatitis C pharmacogenetics: state of the art in 2010. Hepatology 2011; 53: 33645.
  • 23
    Poordad F, Bronowicki JP, Gordon SC, et al. IL28B polymorphism predicts virologic response in patients with Hepatitis C genotype 1 treated with boceprevir combination therapy. J Hepatol 2011; 54: S6.
  • 24
    Jacobson IM, Catlett I, Marcellin P, et al. Telaprevir substantially improved SVR rates across all IL28B genotypes in the Advance trial. J Hepatol 2011; 54: S542.